Six and eight weeks injection frequencies of bevacizumab are non-inferior to the current four weeks injection frequency for quality of life in neovascular age-related macular degeneration: a randomized controlled trial

PURPOSE: Patients with neovascular age-related macular degeneration (nARMD) will not deteriorate on visual acuity and retinal thickness when treated with bevacizumab injection frequencies of 6 or 8 weeks compared to 4 weeks. This study aimed to investigate this non-inferiority in quality of life (Qo...

Descripción completa

Detalles Bibliográficos
Autores principales: Visser, Martijn S., Amarakoon, Sankha, Missotten, Tom, Timman, Reinier, Busschbach, Jan J. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686180/
https://www.ncbi.nlm.nih.gov/pubmed/32666333
http://dx.doi.org/10.1007/s11136-020-02580-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686180/
https://www.ncbi.nlm.nih.gov/pubmed/32666333
http://dx.doi.org/10.1007/s11136-020-02580-9

Ejemplares similares